The current valuation of nearly $200 million has to be including a fair bit for Axiron already. And the Phase III Axiron trial was relatively low risk, so I don't expect the annoucement of results from that to change market sentiment much.
A partnering deal for Axiron, on the other hand, could be a big event, especially if it includes a large up front payment. That should be enough to alleviate any funding issues (and make any capital raisings unnecessary), but it could conceivably be much more - US$100 million or more isn't inconceivable.
A good EU partnership for Ellavie could also be significant. It's a smaller market than the US market, but transdermals make up a larger share of it. And Acrux will be offering a partner a registered drug, not the Phase II success it had when it originally partnered Evamist with Vivus.
- Forums
- ASX - By Stock
- ACR
- price action
price action, page-6
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.2¢ |
Change
-0.005(7.46%) |
Mkt cap ! $18.02M |
Open | High | Low | Value | Volume |
6.5¢ | 6.5¢ | 6.0¢ | $19.14K | 308.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 71240 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 71240 | 0.062 |
1 | 8000 | 0.061 |
3 | 319215 | 0.060 |
1 | 17200 | 0.058 |
1 | 92500 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.067 | 10000 | 1 |
0.068 | 40997 | 1 |
0.069 | 6146 | 1 |
0.070 | 76714 | 1 |
0.072 | 30000 | 1 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online